Merck and partner Ridgeback Biotherapeutics said on Friday six lab studies showed that their experimental oral COVID-19 drug, molnupiravir, was active against the Omicron variant.
Merck's COVID-19 pill effective against Omicron in lab studies
By REUTERS
05/07/2024 07:57 PM
By REUTERS
05/07/2024 02:58 PM
By REUTERS
05/07/2024 02:11 PM
By REUTERS
05/07/2024 01:55 PM
By REUTERS
05/07/2024 01:53 PM
By REUTERS
05/07/2024 01:35 PM
By REUTERS
05/07/2024 12:41 PM
By REUTERS
05/07/2024 12:39 PM
By REUTERS
05/07/2024 12:29 PM
By REUTERS
05/07/2024 11:57 AM
By REUTERS
05/07/2024 11:37 AM
By REUTERS
05/07/2024 11:35 AM